June 25, 2008 MethylGene announces the initiation of a Phase II MGCD0103 randomized, three-arm trial in combination with Vidaza (Trial 013) in patients with high-risk MDS or AML
	June 12, 2008 MethylGene initiates second Phase I clinical trial with MGCD265 in solid tumors
	June 11, 2008 MethylGene to present at the 2008 BIO Business Forum
	June 5, 2008 MethylGene to present at the 7th Annual Needham Conference
	June 3, 2008 Clinical data from a phase II study evaluating MGCD0103 in non-Hodgkin lymphomas (Trial 008) presented at ASCO